

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 April 2024 (11.04.2024)



(10) International Publication Number
WO 2024/076626 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) *A61K 31/4353* (2006.01)
A61K 31/435 (2006.01) *A61K 31/437* (2006.01)
A61K 31/397 (2006.01) *A61K 31/33* (2006.01)

(21) International Application Number:

PCT/US2023/034454

(22) International Filing Date:

04 October 2023 (04.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/413,475 05 October 2022 (05.10.2022) US

(71) Applicants: **OLEMA PHARMACEUTICALS, INC.**

[US/US]: 780 Brannan Street, San Francisco, CA 94103
(US). **NOVARTIS AG** [CH/CH]: Lichtstrasse 35, 4056
Basel (CH).

(72) Inventor: **KLEIN, Pamela M.**; c/o Olema Pharmaceuti-

cals, Inc., 780 Brannan Street, San Francisco, CA 94103
(US).

(74) Agent: **SHINALL, Michael, A.** et al.; Choate, Hall &

Stewart LLP, Two International Place, Boston, MA 02110
(US).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

(54) Title: METHODS OF TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS

(57) **Abstract:** The present disclosure provides methods for treating an estrogen receptor mediated disease, disorder, or condition in a subject comprising administering to the subject a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof in combination with ribociclib, or a pharmaceutically acceptable salt thereof.



Compound 1

WO 2024/076626 A1